Claim · 2026-09-10 · publication · Stated in source · Supported

Insilico Medicine announced on 10 September 2026 that rentosertib had "completed first patient enrollment and dosing" in its Phase III GENESIS-IPF-3 trial at Peking Union Medical College Hospital.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Insilico Medicine: First Patient Enrollment and Dosing in Phase III (GENESIS-IPF-3) of Rentosertib → states provision → company statement: first patient enrolled and dosed in the Phase III GENESIS-IPF-3 trial of rentosertib

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Insilico Medicine: First Patient Enrollment and Dosing in Phase III (GENESIS-IPF-3) of Rentosertibstates provision ↓company statement: first patient enrolled and dosed in the Phase III GENESIS-IPF-3 trial of rentosertib

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Provision: Statement · provision ID co-insilico-rentosertib-phase3-dosing-2026
Date: 2026-09-10 · publication Records dated 2026 →

Scope and limitsThe company's statement of trial progress, not a registry record or a result. Its description of the earlier Phase IIa study as an "industry-first proof of concept" is the company's wording and is not adopted.

The evidence 01

primary sourceSupports the claim

InSilico Medicine Cayman TopCo: Voluntary Announcement - Insilico Medicine Completed First Patient Enrollment and Dosing in Phase III (GENESIS-IPF-3) Clinical Trial of Rentosertib

InSilico Medicine Cayman TopCo, published on HKEXnews · 2026-09-10

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“the Company’s leading AI-driven innovative drug candidate in our pipeline, has completed first patient enrollment and dosing in its Phase III (GENESIS-IPF-3) clinical trial at Peking Union Medical College Hospital”

Location in source first paragraph

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: InSilico Medicine Cayman TopCo, published on HKEXnews
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 4070e953f6bd510c752b3f8f541046111c0d9cb2b499ee8fd1ea046b041abcb4). HKEXnews PDF 2026091000093, listed 2026-09-10, as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: InSilico Medicine Cayman TopCo, published on HKEXnews, “InSilico Medicine Cayman TopCo: Voluntary Announcement - Insilico Medicine Completed First Patient Enrollment and Dosing in Phase III (GENESIS-IPF-3) Clinical Trial of Rentosertib”, 2026-09-10.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (30 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An exact framework edition, or another document with an exact expression, states one provision: a capability threshold or risk level and its trigger, a required safeguard or action, a decision authority (who decides, recommends, can overrule or is informed), a stated exception, or another statement of its content, such as a licence term or a prospectus statement. The passage records what the document says, not implementation, compliance or effectiveness. Provisions with the same key align across editions of one family.

Date. Date of the HKEXnews listing; the announcement does not give the dosing date in the passage read. The record is dated by the text’s date of publication, which is the date of its announcement.

Record ID aib-co-insilico-rentosertib-phase3-dosing-2026